HIV V3 Loop Immunogen Scaffolded by Cholera Toxin B
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccination strategies fail to induce broad neutralization of HIV strains due to the high sequence variability of antibody epitopes, with most antibodies being non-neutralizing or only reactive against limited HIV strains, and existing methods do not effectively elicit protective immunity.
Innovation Solution
A recombinant immunogenic polypeptide is developed by inserting the V3 loop peptide of the HIV gp120 protein into a scaffold protein like Cholera Toxin subunit B (CTB), which preserves the GM1 binding activity and induces a broadly neutralizing antibody response, capable of neutralizing heterologous HIV-1 viruses, and is designed to mimic the conformation recognized by broadly neutralizing antibodies such as 447-52D.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HIV immunogens are used, then the immune response is generated, but the antibodies produced are not neutralizing or have narrow neutralization profiles due to high sequence variability of epitopes
Solution Approach 1:
The patent applies parameter changes by modifying the conformational state of the V3 loop epitope from its native variable state to a constrained beta-turn conformation. This conformational parameter change allows the epitope to present conserved features that are recognized by broadly neutralizing antibodies like 447-52D, thereby overcoming the sequence variability problem while maintaining immunogenicity
Solution Approach 2:
The patent creates a simplified copy of the critical neutralizing epitope features by designing a peptide mimic that replicates the conserved beta-turn conformation of the V3 loop tip. This copied conformational motif, rather than the entire variable gp120 structure, is sufficient to induce broadly neutralizing antibodies, achieving broad protection without the complexity of full gp120 variability
2Productivity
If the V3 loop peptide is inserted into the CTB scaffold, then the immunogenicity is enhanced and broadly neutralizing antibodies are induced, but the structural complexity of the immunogen increases
Solution Approach 1:
The patent merges two distinct functional elements: the highly immunogenic CTB scaffold protein and the neutralizing V3 loop peptide epitope. The CTB pentamer provides robust immunogenicity and mucosal adjuvant activity, while the inserted V3 loop peptide provides the specific neutralizing epitope. This combination achieves high antibody titers with broad neutralization capability
Solution Approach 2:
The patent segments the immunogen into modular components: the CTB scaffold (residues 1-124) and the inserted V3 loop peptide (residues corresponding to positions 317-354 of gp120). This segmentation allows independent optimization of each component's function while maintaining overall structural integrity and immunogenicity
3Reliability
If focus is placed on conserved regions of gp120 to induce neutralizing antibodies, then neutralization efficacy improves, but the response remains strain-specific due to epitope variability
Solution Approach 1:
The patent changes the conformational parameter of the V3 loop from its native extended state to a constrained beta-turn structure. This conformational change exposes conserved features that are less variable across strains, allowing antibodies induced by this conformation to recognize multiple HIV strains more effectively than antibodies induced by the native variable conformation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach induces high titers of antibodies with a binding mode and epitope specificity similar to known broadly neutralizing antibodies, resulting in effective neutralization of heterologous HIV-1 viruses, including those with different subtypes and clades, and provides mucosal immunity.
Implementation Method 1
An important factor for the immunogenic property of CTB and related toxins is their binding to GM1 ganglioside. X-ray structures of CTB revealed that the oligosaccharide binding sites are formed by residues E51, Q56, H57, Q61, W88, N90, and K91
Implementation Method 2
447-52D recognizes the conserved tip of the V3 loop in a beta-turn conformation. A specially designed V3-based immunogen that could induce high titers of antibodies with a binding mode and epitope specificity that is similar to that of one or more known broadly neutralizing antibodies
Data Source
AI summary
Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related E. coli enterotoxins. Such immunogenic polypeptides induce broadly reactive anti-gp120 antibodies specific for V3 epitopes that can neutralize heterologous HIV-1 subtypes and strains. These polypeptide, methods for preparing them, and methods for inducing anti-gp120 (V3-specific) antibody) responses using them are disclosed.